Marein Reverses Cancer Drug Resistance via ABCG2 Inhibition

Study Background and Research Question

Drug resistance remains a central obstacle in effective cancer chemotherapy. Many tumors, after initial response, develop multidrug resistance (MDR) through various mechanisms, most notably via increased expression of ATP-binding cassette (ABC) transporters that actively extrude chemotherapeutic agents from cells. Among these, ABCG2—also known as breast cancer resistance protein (BCRP)—is highly implicated in resistance to drugs such as topotecan, mitoxantrone, and olaparib, especially in breast, colon, and melanoma cancers. While several synthetic and natural ABCG2 inhibitors have been developed, clinical translation is hampered by off-target toxicity or insufficient efficacy. The study by Li et al. (Biochemical Pharmacology, 2024) investigates whether marein, a natural chalcone glycoside from Coreopsis tinctoria, can serve as a novel, less toxic chemo-sensitizer by competitively inhibiting ABCG2.

Key Innovation from the Reference Study

The primary innovation is the identification of marein as a potent, competitive, and selective inhibitor of ABCG2. The study shows that marein directly binds to the conserved F439 residue within the ABCG2 transmembrane domain, a key site for substrate interaction and efflux activity. This binding competitively blocks the transporter, leading to increased intracellular retention of ABCG2 substrate drugs. Unlike many previously described inhibitors, marein demonstrates low intrinsic cytotoxicity, suggesting potential for safer combinatorial use with chemotherapeutics.

Methods and Experimental Design Insights

The experimental workflow employed by Li et al. is notable for its multi-layered approach:

• Cell viability and cytotoxicity assays: Cancer cell lines with varying ABCG2 expression levels were treated with chemotherapeutic substrates in the presence or absence of marein, assessing cell survival and drug sensitivity.
• Drug accumulation assays: The team quantified intracellular concentrations of ABCG2 substrate drugs via LC–MS/MS, demonstrating increased accumulation upon marein co-treatment.
• Efflux inhibition studies: The efflux function of ABCG2 was assessed using fluorescent and non-fluorescent substrates, confirming marein’s competitive inhibition profile.
• Protein-ligand interaction analyses: Cellular thermal shift assays (CETSAs) and drug-affinity responsive target stability (DARTS) techniques established direct binding of marein to ABCG2, pinpointing the F439 residue as the interaction hub.
• Western blotting: Used to confirm ABCG2 expression levels across the studied cell models.

This methodical combination of functional and binding assays allowed the authors to delineate both the mechanism and selectivity of marein’s action.

Core Findings and Why They Matter

The study’s key findings include:

• Marein competitively inhibits ABCG2: By occupying the substrate-binding site, marein prevents efflux of chemotherapeutic drugs, increasing their intracellular concentration and cytotoxic efficacy.
• Binding specificity: Marein’s interaction with F439—a conserved residue crucial for ABCG2 function—was confirmed via mutational analysis, supporting its high selectivity.
• Restoration of drug sensitivity: In ABCG2-overexpressing cancer cells, marein co-treatment resensitized cells to topotecan, mitoxantrone, and olaparib, resulting in marked reductions in cell viability compared to drug alone (reference study).
• Low intrinsic toxicity: Marein did not induce significant cytotoxicity in the absence of chemotherapeutics, highlighting its potential for safe co-administration.

These results suggest that marein could be deployed as an adjuvant to restore chemosensitivity in MDR tumors, particularly those with elevated ABCG2 activity.

Comparison with Existing Internal Articles

While the reference study focuses on ABCG2, past research and internal resources have centered on ABCB1 (P-glycoprotein, MDR1) and other ABC transporters. For instance, Rhodamine 123 (chloride): Transforming P-Glycoprotein Efflux Assays and Rhodamine 123 for Real-Time P-Glycoprotein Efflux Pump Assays detail how membrane-permeable fluorescent dyes enable real-time, quantitative analysis of membrane transport, especially for dissecting P-glycoprotein and OATP1A2 function. These workflows are pivotal for understanding drug efflux and uptake, informing the design of assays to test both ABCB1 and ABCG2 modulation. Notably, the workflow advances described in Advanced Workflows for Efflux Assays—including live-cell fluorescent substrate accumulation and efflux quantification—are directly applicable for evaluating ABC transporter inhibitors like marein. While Rhodamine 123 is primarily a substrate for ABCB1 and OATP1A2, similar assay principles and troubleshooting approaches can be transposed to ABCG2 research, making these internal articles valuable resources for labs expanding their transporter studies.

Protocol Parameters

• Cell density: Plate cells at 5 × 10⁴–1 × 10⁵ cells/well for efflux or accumulation assays, ensuring logarithmic growth phase for optimal transporter activity.
• Marein treatment: Administer marein 1–2 hours prior to and during exposure to chemotherapeutic substrate; typical working concentrations ranged from 1–10 μM in the reference study, with dose-response curves recommended for optimization.
• Substrate incubation: Incubate cells with ABCG2 substrate drugs (e.g., mitoxantrone, topotecan) for 30–60 minutes at 37°C, with or without marein, before washing and measurement.
• Drug accumulation measurement: Quantify intracellular drug by LC–MS/MS or fluorescence, normalizing to total protein content.
• Efflux assay controls: Include both transporter-overexpressing and parental cell lines, with and without known ABCG2 inhibitors, to validate specificity.

For laboratories interested in related ABCB1/MDR1 or OATP1A2-mediated transport workflows, refer to the best practices outlined in internal articles on Rhodamine 123 (chloride) assays.

Limitations and Transferability

Despite promising in vitro evidence, several limitations warrant consideration:

• Lack of in vivo validation: The study’s findings are currently restricted to cell culture models. Further preclinical work is needed to confirm marein’s efficacy and safety in animal models of drug-resistant cancer.
• Transporter specificity: While marein shows high affinity for ABCG2, its selectivity against other ABC transporters (such as ABCB1 or ABCC1) was not exhaustively profiled.
• Potential pharmacokinetic interactions: As a polyphenolic compound, marein may interact with metabolic enzymes or off-target proteins, which could influence its translational potential.

Transferability of these findings to clinical contexts will require further investigation, including in vivo pharmacodynamics, toxicity, and combinatorial regimens with established chemotherapeutics.

Research Support Resources

For researchers seeking to investigate ABC transporter function and modulation, fluorescent substrate-based efflux and accumulation assays remain the gold standard. Tools like Rhodamine 123 (chloride) (SKU C3140) offer reliable, real-time readouts for membrane transport process analysis, especially in the context of ABCB1/MDR1 and OATP1A2-related studies. Its compatibility with live-cell protocols and sensitive detection make it a robust choice for optimizing drug transport assays, as discussed in scenario-driven guides such as Reliable Efflux Assays for ABC Transporters. While Rhodamine 123 is not a substrate for ABCG2, the protocol structure and troubleshooting strategies described in internal articles translate well to ABCG2-focused work, including the assessment of novel inhibitors like marein. For detailed assay design and workflow support, consult the product information and relevant internal resources. APExBIO supports research-only applications of Rhodamine 123 (chloride); it is not approved for clinical or diagnostic use.